We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
+16.2%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$126M
AUM Growth
+$27.3M
(+27%)
Cap. Flow
+$10M
Cap. Flow
% of AUM
7.93%
Top 10 Holdings %
Top 10 Hldgs %
54.03%
Holding
70
New
10
Increased
16
Reduced
10
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$3.68M |
| 2 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$3.29M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.09M |
| 4 |
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
|
+$1.56M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$1.51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XNPT
XENOPORT, INC.
XNPT
|
+$1.04M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$1.04M |
| 3 |
BSTC
BioSpecifics Technologies Corp.
BSTC
|
+$1.01M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$683K |
| 5 |
Vericel Corp
VCEL
|
+$681K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 60.28% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
BioLife Solutions
BLFS
$1.55B
| $191K | 0.15% |
116,279
| – | – |
|
52
Protara Therapeutics
TARA
$227M
| $132K | 0.1% |
+318
| New | +$128K |
|
|
CEMI
53
DELISTED
Chembio diagnostics, Inc.
CEMI
| $103K | 0.08% |
26,287
-28,915
| -52% | -$120K |
|
|
GBIM
54
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
| $83K | 0.07% |
10,945
+200
| +2% | +$1.39K |
|
55
InspireMD
NSPR
$31.5M
| – | – |
0
| – | – |
|
56
Curis
CRIS
$9.67M
| – | – |
-75
| Closed | -$212K |
|
|
57
Neurocrine Biosciences
NBIX
$18.7B
| – | – |
-66,141
| Closed | -$1.04M |
|
58
Retractable Technologies
RVP
$20.1M
| – | – |
-20,000
| Closed | -$58K |
|
59
SCYNEXIS
SCYX
$37M
| – | – |
-625
| Closed | -$370K |
|
60
Tonix Pharmaceuticals
TNXP
$161M
| – | – |
0
| – | -$171K |
|
|
61
Vericel Corp
VCEL
$2.43B
| – | – |
-238,900
| Closed | -$681K |
|
|
AMPE
62
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| – | – |
-500
| Closed | -$530K |
|
|
CASC
63
DELISTED
Cascadian Therapeutics, Inc.
CASC
| – | – |
-35,829
| Closed | -$413K |
|
Similar funds
CDMG
STCG
SCP
CAAM
HCM
CPW
BOA
ECA
DAFNA Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, DAFNA Capital Management held 70 positions worth $126M, up 27% from $99.1M the previous quarter. Its ten largest holdings account for 54% of the portfolio.
DAFNA Capital Management deployed $10M of net new capital in Q4 2014, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was XENOPORT, INC., an estimated $1.04M trimmed.
- DAFNA Capital Management's largest Q4 2014 buy was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.
- DAFNA Capital Management added most to Intercept Pharmaceuticals, Inc. in Q4 2014, an estimated $3.68M increase.
- DAFNA Capital Management's biggest Q4 2014 reduction was XENOPORT, INC., cutting an estimated $1.04M.
- DAFNA Capital Management fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $1.04M.
- DAFNA Capital Management's ten largest holdings make up 54% of its $126M portfolio in Q4 2014.
- DAFNA Capital Management opened 10 new positions and closed 7 in Q4 2014.
- DAFNA Capital Management's portfolio value rose 27% quarter-over-quarter to $126M.
Based on DAFNA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.